Skip to main content
Clinical Trials/CTRI/2025/09/095072
CTRI/2025/09/095072
Not yet recruiting
Phase 3

An Interventional Study To Assess The Effectiveness Of Bacillus Morgan Pure In Case Of Dermatitis.

Dr MPK Homoeopathy Medical College Hospital and Research Centre1 site in 1 country60 target enrollmentStarted: October 2, 2025Last updated:

Overview

Phase
Phase 3
Status
Not yet recruiting
Sponsor
Dr MPK Homoeopathy Medical College Hospital and Research Centre
Enrollment
60
Locations
1
Primary Endpoint
According to scores obtained (pre and post treatment ) from Dermatology Life Quality Index (DLQI) .

Overview

Brief Summary

This study is prospective, uncontrolled, open label, single arm , unicentric, experimental, clinical study to assess the effectiveness of bowel nosode  Bacillus morgan pure in cases of Dermatitis. This study will evaluate the extent of improvement in dermatitis cases using DLQI scale. The primary outcome will be according to the scores obtained (pre and post treatment)from DLQI scale.

Null hypothesis - There is no significant improvement assessed through pre and post DLQI score in the management of dermatitis by prescribing homoeopathic bowel nosode BACILLUS MORGAN PURE

Alternate hypothesis - There is a significant improvement assessed through pre and post DLQI score in the management of dermatitis by prescribing homoeopathic bowel nosode BACILLUS MORGAN PURE

Study Design

Study Type
Interventional
Allocation
Na
Masking
None

Eligibility Criteria

Ages
18.00 Year(s) to 60.00 Year(s) (—)
Sex
All

Inclusion Criteria

  • Patients who are willing to give consent and willing to take Homeopathic Treatment and follow up regularly The medicine is given to those patients who have symptoms similar to Bacillus Morgan Pure , i.e burning, itching, scalding, redness, heat, fissures, dryness oozing, eruptions , generally aggravate by heat, washing, at night.

Exclusion Criteria

  • Cases with multi systemic illness will be excluded from the study and cases with advanced pathology Pregnant women and lactating mothers Immuno Compromised patients such as those sufferings from HIV, Hepatitis-B ,C etc.
  • Patients who are not willing to give consent and taking other treatments for Dermatitis.

Outcomes

Primary Outcomes

According to scores obtained (pre and post treatment ) from Dermatology Life Quality Index (DLQI) .

Time Frame: 6 months

Secondary Outcomes

  • Bacillus Morgan Pure selected will be effective in managing the cases of Dermatitis. It is expected that Bacillus Morgan Pure will improve the frequency and intensity of Dermatitis and improve quality of life of patient.(12 months)

Investigators

Sponsor
Dr MPK Homoeopathy Medical College Hospital and Research Centre
Sponsor Class
Private medical college
Responsible Party
Principal Investigator
Principal Investigator

Dr Divya Singh

Homoeopathy University

Study Sites (1)

Loading locations...

Similar Trials